相似文献
1
Getting the Right Evidence After Drug Approval.
Front Pharmacol. 2020 Sep 9;11:569535. doi: 10.3389/fphar.2020.569535. eCollection 2020.
2
Evidence-based decision on medical technologies in Asia Pacific: experiences from India, Malaysia, Philippines, and Pakistan.
Value Health. 2009 Nov-Dec;12 Suppl 3:S18-25. doi: 10.1111/j.1524-4733.2009.00622.x.
3
Pharmaceutical pricing and reimbursement in China: When the whole is less than the sum of its parts.
Health Policy. 2016 May;120(5):519-34. doi: 10.1016/j.healthpol.2016.03.014. Epub 2016 Apr 12.
4
New Drug Reimbursement and Pricing Policy in Taiwan.
Value Health Reg Issues. 2018 May;15:127-132. doi: 10.1016/j.vhri.2018.03.004. Epub 2018 Apr 26.
5
Analysing criteria for price and reimbursement of orphan drugs in Spain.
Farm Hosp. 2019 Jul 1;43(4):121-127. doi: 10.7399/fh.11147.
6
Drug pricing and reimbursement decision making systems in Mongolia.
J Pharm Policy Pract. 2017 Feb 27;10:11. doi: 10.1186/s40545-017-0098-6. eCollection 2017.
7
Comparing patient access to pharmaceuticals in the UK and US.
Appl Health Econ Health Policy. 2006;5(3):177-87. doi: 10.2165/00148365-200605030-00004.
8
Pharmaceutical Pricing and Reimbursement in Japan: For Faster, More Complete Access to New Drugs.
Ther Innov Regul Sci. 2016 May;50(3):361-367. doi: 10.1177/2168479015619202.
9
Reimbursement of Orphan Drugs in Europe in Relation to the Type of Authorization by the European Medicines Agency and the Decision Making Based on Health Technology Assessment.
Front Pharmacol. 2018 Nov 12;9:1263. doi: 10.3389/fphar.2018.01263. eCollection 2018.
10
How Can Pricing and Reimbursement Policies Improve Affordable Access to Medicines? Lessons Learned from European Countries.
Appl Health Econ Health Policy. 2017 Jun;15(3):307-321. doi: 10.1007/s40258-016-0300-z.
引用本文的文献
1
Managed Entry Agreements for High-Cost, One-Off Potentially Curative Therapies: A Framework and Calculation Tool to Determine Their Suitability.
Pharmacoeconomics. 2025 Jan;43(1):53-66. doi: 10.1007/s40273-024-01433-4. Epub 2024 Oct 5.
2
Added benefit and revenues of oncology drugs approved by the European Medicines Agency between 1995 and 2020: retrospective cohort study.
BMJ. 2024 Feb 28;384:e077391. doi: 10.1136/bmj-2023-077391.
3
Synergy between health technology assessments and clinical guidelines for multiple sclerosis.
Clin Transl Sci. 2023 May;16(5):835-849. doi: 10.1111/cts.13492. Epub 2023 Mar 1.
4
Real World Data in Health Technology Assessment of Complex Health Technologies.
Front Pharmacol. 2022 Feb 10;13:837302. doi: 10.3389/fphar.2022.837302. eCollection 2022.
5
An urgent call to raise the bar in oncology.
Br J Cancer. 2021 Nov;125(11):1477-1485. doi: 10.1038/s41416-021-01495-7. Epub 2021 Aug 16.
6
Application of Managed Entry Agreements for Innovative Therapies in Different Settings and Combinations: A Feasibility Analysis.
Int J Environ Res Public Health. 2020 Nov 10;17(22):8309. doi: 10.3390/ijerph17228309.
本文引用的文献
1
Generating comparative evidence on new drugs and devices after approval.
Lancet. 2020 Mar 21;395(10228):998-1010. doi: 10.1016/S0140-6736(19)33177-0.
2
Comparative Approaches to Drug Pricing.
Annu Rev Public Health. 2020 Apr 2;41:499-512. doi: 10.1146/annurev-publhealth-040119-094305. Epub 2019 Dec 24.
3
Design characteristics, risk of bias, and reporting of randomised controlled trials supporting approvals of cancer drugs by European Medicines Agency, 2014-16: cross sectional analysis.
BMJ. 2019 Sep 18;366:l5221. doi: 10.1136/bmj.l5221.
4
Added therapeutic benefit and drug licensing.
Nat Rev Drug Discov. 2019 Sep;18(9):651-652. doi: 10.1038/d41573-019-00068-x.
5
How to Choose the Best Treatment and Testing for Chronic Lymphocytic Leukemia in the Tsunami of New Treatment Options.
Curr Oncol Rep. 2019 Jul 20;21(8):74. doi: 10.1007/s11912-019-0819-x.
6
Current Policy and Practice for Value-Based Pricing.
Value Health. 2019 Jun;22(6S):S4-S6. doi: 10.1016/j.jval.2019.04.1918.
7
An Overview of Cancer Drugs Approved by the US Food and Drug Administration Based on the Surrogate End Point of Response Rate.
JAMA Intern Med. 2019 Jul 1;179(7):915-921. doi: 10.1001/jamainternmed.2019.0583.
8
Analysis of Postapproval Clinical Trials of Therapeutics Approved by the US Food and Drug Administration Without Clinical Postmarketing Requirements or Commitments.
JAMA Netw Open. 2019 May 3;2(5):e193410. doi: 10.1001/jamanetworkopen.2019.3410.
9
The evolution of adaptiveness: balancing speed and evidence.
Nat Rev Drug Discov. 2018 Dec;17(12):845-846. doi: 10.1038/nrd.2018.90. Epub 2018 Jul 6.
10
Postauthorization Changes to Specific Obligations of Conditionally Authorized Medicines in the European Union: A Retrospective Cohort Study.
Clin Pharmacol Ther. 2019 Feb;105(2):426-435. doi: 10.1002/cpt.1169. Epub 2018 Aug 12.
Zotero 插件